… Physician's choice not to randomise after 1 year was another … to adjust antiplatelet therapy
versus standard of care: rationale … covariate to assess the effect of patients who crossed over. …

… Effects of pretreatment … continued indefinitely and clopidogrel should be continued for up
to 9 to 12 months 43 and possibly longer, depending on the physician’s estimate of the patient’s …

… that the initial heparin treatment affects the long-term outcome. This conclusion applies when
these data are analyzed for each individual study by treatment group, observed difference …

… Each JACC Patient Care Pathway is an immersive, multimedia … clinical impact of different
cessation patterns of dual-antiplatelet … In aggregate, these findings suggest that physicians are …

… Future studies should continue to examine the mechanisms … physicians [1, 3] , including
increased use of antiplatelets [3] , … compared to patients who received generalist care only, yet …

… with a recent coronary stent, the decision to continue clopidogrel until the time of surgery
or to discontinue will depend on the risk and potential impact of stent thrombosis. Restarting …

… assessed unselected patients from tertiary care hospitals with … 9961 patients randomly
assigned to continue thienopyridine … patients without PAD, we did not observe a significant effect …

… s ability to diagnose and care for patients with the entire spectrum of … within one hour;
physicians should claim only those credits … studies, antiplatelet therapy also has a relevant effect …

… was to assess the effect of using dual-antiplatelet therapy for 6 … treating physician performed
allocation of study treatment … the assigned treatment schedule, returned for study visits at 30 …

… In between, the patients were under the care of their general … groups; and general practitioner's
or patient's decision (9.3%). … also investigated antithrombotic treatment in patients with AF …